Vertex Pharmaceuticals Incorporated

VRTX · NASDAQ · USD

Can Vertex convert its cystic fibrosis cash flow into renal and pain franchises quickly enough to offset a shrinking TRIKAFTA and a successor pipeline that may not beat ALYFTREK?

Last 4 earnings calls · through Q2 FY2026

Bull case

  • CF switch to once-daily pill

    Vertex keeps its cystic fibrosis franchise growing by moving patients to a once-daily medicine that covers more mutations and reaches younger children.

  • Renal launch nears approval

    A kidney medicine filed for approval turns a long-discussed pipeline into a near-term launch that management says could one day match cystic fibrosis.

  • CASGEVY and JOURNAVX revenue

    Gene therapy and the non-opioid pain drug add revenue outside cystic fibrosis, giving Vertex new growth lines while its core franchise matures.

  • Cash funds pipeline and deals

    High margins and strong free cash flow pay for clinical trials, launch build-outs and acquisitions without leaning on the balance sheet.

Bear case

  • Cystic fibrosis concentration

    Nearly all revenue still comes from cystic fibrosis, and the largest product is shrinking as patients move to the newer once-daily medicine.

  • Successor CF pipeline unclear

    Management now says beating its own cystic fibrosis drug is very hard, so next-generation candidates may add little and one program was dropped.

  • Pain revenue lags prescriptions

    JOURNAVX prescriptions are growing quickly, but payer restrictions keep patients on support programs, so revenue lags and the margin fix keeps slipping.

  • Acquisition cost and focus

    The Crinetics purchase is large, partly debt-funded and not expected to add to operating income for years, spreading attention across a fifth disease area.

Bull and bear points

Growth & Execution

In short: ALYFTREK and a near-term renal launch drive growth, while CF switching cannibalizes TRIKAFTA revenue.

Bull · 2

  • ALYFTREK now carries CF growth as patients switch

    ALYFTREK revenue reached $574 million in the second quarter and the medicine has passed $1 billion cumulatively, so the cystic fibrosis franchise grows even as its older product declines.

    Q2 FY2026 call

  • Renal launch moves from plan to filed application

    A year ago management framed renal as a growth driver over several years; now the IgAN application is accepted with a November 30 decision date and the sales force is hired.

    Tone shiftQ3 FY2025 → Q2 FY2026
Bear · 1

  • Beating ALYFTREK is now a very high bar

    Earlier calls called VX-828 the most efficacious corrector studied; management now says unmet need is far lower and only assets that beat ALYFTREK will advance past early testing.

    Tone shiftQ4 FY2025 → Q2 FY2026

Profitability & Financial Strength

In short: Free cash flow and operating margins stay strong, while product mix and launch costs pressure gross margin.

Bull · 2

  • Free cash flow covers investment and buybacks

    Free cash flow of $3.8 billion over the last twelve months equals 30% of revenue, paying for pipeline spending, launch build-out and share repurchases without new borrowing.

    Q2 FY2026 call

  • Operating margin near 37% despite launch spending

    Operating margin of 37.4% held up even as selling costs for pain and renal rose, because research spending grew only slightly while revenue grew far faster.

    Q2 FY2026 call
Bear · 3

  • Gross margin slips as gene therapy and biologics grow

    Gross margin fell to 85.3% as higher-cost CASGEVY and manufacturing investments enter the product mix, and management expects the drag to be larger in the second half.

    Q2 FY2026 call

  • Pain revenue conversion slips to first half 2027

    Management previously expected gross-to-net to normalize in late 2026 or early 2027; it now points to the first half of 2027 because prescriptions are outrunning payer access.

    Tone shiftQ4 FY2025 → Q2 FY2026

  • Crinetics deal adds debt before it adds profit

    The acquisition is funded partly with a $4.5 billion term loan and management does not expect it to add to operating income until 2029, so earnings carry the cost first.

    Q2 FY2026 call

Market Position

In short: Vertex treats most CF patients with its own drugs, but concentration and IgAN competition limit pricing power.

Bull · 2

  • Label expansion covers about 95% of CF patients

    Regulators let ALYFTREK and TRIKAFTA cover patients based on clinical diagnosis and lab data, extending treatment to about 95% of people with CF, including rare and one-of-a-kind genotypes.

    Q1 FY2026 call

  • NOPAIN Act gives JOURNAVX separate Medicare payment

    The medicine was added to the list of non-opioid treatments eligible for separate payment under the NOPAIN Act, which removes a payment barrier in hospital outpatient and surgery center settings.

    Q1 FY2026 call
Bear · 2

  • TRIKAFTA supplies 78% of segment revenue and is shrinking

    TRIKAFTA and KAFTRIO revenue fell 2.1% year on year as patients moved to ALYFTREK, so the franchise depends on converting users faster than the older product erodes.

    Filed financials

  • IgA nephropathy is a crowded, first-mover market

    Vertex launches its kidney drug behind an approved rival, and management itself describes competitive intensity in IgAN as far higher than in membranous nephropathy.

    Q3 FY2025 call